Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aikelian Biotechnology

Request full access

Next-generation T-cell engager immunotherapies for solid tumors.

Jing'an District, ChinaFounded 2025Biotech & Life Sciences

About Aikelian Biotechnology

Aikelian Biotechnology, operating as Excalipoint Therapeutics, is a clinical-stage biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases. The company was established in Shanghai, China, in August 2025, operating under a “NewCo” model that integrates experienced founders, venture capital, and pipeline assets to accelerate drug development.

Excalipoint was co-founded by CEO Dr. Lei Fang and CFO/CBO Jielun Zhu. Dr. Fang has a background in immunology and T-cell biology, with previous leadership roles at Lepu Biopharma and I-Mab Biopharma. Mr. Zhu contributes over 20 years of experience in healthcare and capital markets. The company launched with an oversubscribed seed financing of $68.7 million, one of the largest for a Chinese biotech startup. This included an initial $41 million at its inception and a $27.7 million extension six months later. The funding round was supported by a syndicate of top-tier investors, including HSG, Apricot Capital, Yuanbio Venture Capital, Lilly Asia Ventures, and Eisai's venture arm, Eisai Innovation.

The company's business model is focused on developing a portfolio of antibody drugs and proprietary platforms to overcome the limitations of existing TCE therapies, particularly in treating solid tumors. Excalipoint is developing three main technology platforms: TOPAbody, T-Cell Immune Shield, and TCE Probody. These platforms are designed to enhance the efficacy and safety of immunotherapies by addressing challenges such as converting immunologically "cold" tumors to "hot" ones and mitigating the immunosuppressive tumor microenvironment. The company's pipeline consists of six differentiated programs. Its lead candidate, EXP011, is a tri-specific antibody targeting DLL3, CD3, and 4-1BB for malignancies like small-cell lung cancer and neuroendocrine tumors. A Phase I/II clinical trial for EXP011 began in October 2025. A second program, EXP012, is a trispecific antibody for gastrointestinal cancers.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
57.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Oncology, Antibodies, Immune System, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Mar 2026 $28M $111M Apricot Capital · 5Y Capital · Eisai Innovation · Lilly Asia Ventures ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Aikelian Biotechnology website traffic

Latest recorded traffic for Aikelian Biotechnology is 40 monthly website visits.

Latest monthly visits40
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Aikelian Biotechnology in the Jing'an District ecosystem

Live from Dealroom

The Aikelian Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aikelian Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aikelian Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.